Long-term Oral Galactose Treatment Prevents Cognitive Deficits in Male Wistar Rats Treated Intracerebroventricularly with Streptozotocin.

Department of Pharmacology and Croatian Institute for Brain Research, School of Medicine, University of Zagreb, 10 000 Zagreb, Croatia. Electronic address: .
Neuropharmacology (Impact Factor: 4.82). 09/2013; 77. DOI: 10.1016/j.neuropharm.2013.09.002
Source: PubMed

ABSTRACT Basic and clinical research has demonstrated that dementia of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells. An alternative source of energy is D-galactose (the C-4-epimer of D-glucose) which is transported into the brain by insulin-independent GLUT3 transporter where it might be metabolized to glucose via the Leloir pathway. Exclusively parenteral daily injections of galactose induce memory deterioration in rodents and are used to generate animal aging model, but the effects of oral galactose treatment on cognitive functions have never been tested. We have investigated the effects of continuous daily oral galactose (200 mg/kg/day) treatment on cognitive deficits in streptozotocin-induced (STZ-icv) rat model of sAD, tested by Morris Water Maze and Passive Avoidance test, respectively. One month of oral galactose treatment initiated immediately after the STZ-icv administration, successfully prevented development of the STZ-icv-induced cognitive deficits. Beneficial effect of oral galactose was independent of the rat age and of the galactose dose ranging from 100 to 300 mg/kg/day. Additionally, oral galactose administration led to the appearance of galactose in the blood. The increase of galactose concentration in the cerebrospinal fluid was several times lower after oral than after parenteral administration of the same galactose dose. Oral galactose exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of cognitive deficits associated with glucose hypometabolism in AD.

Download full-text


Available from: Melita Salkovic-Petrisic, Aug 22, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent advances in the understanding of the pathophysiological mechanisms underlying Alzheimer's disease and other cognitive deficits have pointed to novel strategies for drug development. Animal models have contributed noticeably to these advances and are an indispensible part in the evaluation of therapeutics. This review is an exhaustive study of animal models of dementia and cognitive dysfunction. A thorough and critical evaluation of current rodent models of dementia, and discussion about their role in drug discovery and development have been carried out. Since dementia has multiple pathophysiological mechanisms, we have tried to provide a detailed description of various types of animal models which would depict different pathophysiological stages and causes of dementia. This review aims to better understand the prognosis, biochemical, and behavioral alterations that occur during dementia and hence facilitate drug discovery and development.
    Life Sciences 07/2014; 109(2). DOI:10.1016/j.lfs.2014.05.017 · 2.30 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The status of this article is IN PRESS which means that it may still undergo some minor changes until being assigned to an issue. Use the following items to reference the IN PRESS article: author(s) name(s), article title, journal name, online publication year and DOI. Do not use page numbers.
    Acta Societatis Botanicorum Poloniae 01/2014; · 1.20 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The spontaneously hypertensive rat (SHR) has been used to model changes in the central nervous system associated with cognitive-related disorders. Recent human and animal studies indicate a possible relationship between cognitive deficits, insulin resistance and hypertension. We aimed to investigate whether cognitively impaired SHRs develop central and/or peripheral insulin resistance and how their cognitive performance is influenced by the animal's sex and age as well as strains used for comparison (Wistar and Wistar-Kyoto/WKY). Three and seven-month-old SHR, Wistar, and WKY rats were studied for their cognitive performance using Morris Water Maze (MWM) and Passive Avoidance tests (PAT). Plasma glucose and insulin were obtained after oral glucose tolerance tests. Cerebral cortex, hippocampus, and striatum status of insulin-receptor (IR) β-subunit and glycogen synthase kinase-3β (GSK3β) and their phosphorylated forms were obtained via ELISA. SHRs performed poorly in MWM and PAT in comparison to both control strains but more pronouncedly compared to WKY. Females performed poorer than males and 7-month-old SHRs had poorer MWM performance than 3-month-old ones. Although plasma glucose levels remained unchanged, plasma insulin levels were significantly increased in the glucose tolerance test in 7-month-old SHRs. SHRs demonstrated reduced expression and increased activity of IRβ-subunit in cerebral cortex, hippocampus, and striatum with different regional changes in phospho/total GSK3β ratio, as compared to WKYs. Results indicate that cognitive deficits in SHRs are accompanied by both central and peripheral insulin dysfunction, thus allowing for the speculation that SHRs might additionally be considered as a model of insulin resistance-induced type of dementia.
    12/2015; 3(1). DOI:10.1186/s40303-015-0012-6